Article Details
Retrieved on: 2025-08-16 17:17:46
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Wedbush has a “Outperform” rating and a $35.00 price target on the stock. Wedbush also issued estimates for Zenas BioPharma's Q4 2025 earnings at ($ ...
Article found on: www.defenseworld.net
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here